Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) FCF Margin (2016 - 2025)

Coherus Oncology's FCF Margin history spans 12 years, with the latest figure at 220.36% for Q4 2025.

  • For Q4 2025, FCF Margin fell 59031.0% year-over-year to 220.36%; the TTM value through Dec 2025 reached 786.76%, up 55914.0%, while the annual FY2025 figure was 786.76%, 89.0% up from the prior year.
  • FCF Margin for Q4 2025 was 220.36% at Coherus Oncology, up from 400.48% in the prior quarter.
  • Across five years, FCF Margin topped out at 6111.66% in Q1 2024 and bottomed at 401.96% in Q1 2025.
  • The 5-year median for FCF Margin is 72.39% (2023), against an average of 484.99%.
  • The largest annual shift saw FCF Margin skyrocketed 632402bps in 2024 before it crashed -651362bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 71.97% in 2021, then tumbled by -207bps to 220.59% in 2022, then skyrocketed by 94bps to 14.17% in 2023, then skyrocketed by 2710bps to 369.95% in 2024, then crashed by -160bps to 220.36% in 2025.
  • Per Business Quant, the three most recent readings for CHRS's FCF Margin are 220.36% (Q4 2025), 400.48% (Q3 2025), and 4259.49% (Q2 2025).